All posts by admin

Business Wire India

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced first quarter debt reduction activities and a recent amendment to its credit agreement.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401160360/en/

 

 

 

• Debt reduction activities during the first quarter of 2026 totaled $10.9 million, reducing the Company’s outstanding term loan to $58.4 million as of March 31, 2026.
• The Company’s credit agreement was amended effective as of March 27, 2026 to increase to $20.0 million the value of Company common stock that could be repurchased per annum, beginning with the Company’s 2026 fiscal year and for each fiscal year thereafter, with a revised total of $50.0 million in permitted stock repurchases from the period beginning January 1, 2026 through the maturity of the facility on April 30, 2029. The Company’s Board previously authorized common stock repurchases of up to $50.0 million, of which $36.7 million remains available until April 2029.

“These actions support our disciplined deployment of resources to drive shareholder value through investments in the business, debt reduction and common share repurchases,” said Seth Ravin, president and CEO, Rimini Street.

 

About Rimini Street, Inc.

 

 

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation.

 

 

To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

 

 

Forward-Looking Statements

 

 

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for enterprise resource planning (ERP) software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; our wind down of support services for Oracle PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately forecast retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs, including those imposed by the United States government and the potential for retaliatory trade measures by affected countries; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States government and international governments and capture new contracts with governmental entities/agencies; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Annual Report on Form 10-K filed on February 19, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

 

 

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401160360/en/

 

Business Wire India

 

• Fraudulent disputes and administrative inefficiencies drive billions in avoidable economic costs
• Six new and enhanced dispute resolution tools utilize AI and proprietary technology to help provide issuers, acquirers and merchants with increased visibility into costly fraud expenses

 

Visa (NYSE: V), a global leader in digital payments, today announced six new dispute resolution tools designed to reduce the billions of dollars lost annually to inefficient, outdated dispute processes. The expanded suite of dispute resolution services is being designed to help merchants and financial institutions cut administrative costs, reduce fraud-related losses and redirect those resources toward growth, innovation and customer experience.

 

Disputes remain one of the most persistent friction points in commerce, driving rising costs for merchants and financial institutions while simultaneously leaving consumers frustrated and confused. In 2025, Visa processed 106 million disputes globally, a 35% increase since 2019¹.

 

 

“Dispute management is moving from a back-office function to a strategic priority, driven by rising volumes, regulatory scrutiny, and growing pressure to protect customer experience,” says Sam Abadir, Research Director, Risk, Compliance & Financial Crime, IDC Financial Insights. “Institutions that continue to manage disputes through fragmented, manual processes are leaving recoverable revenue on the table and absorbing costs that modern workflows could eliminate.”

 

 

New & Enhanced Dispute Resolution Tools for Merchants

 

 

• Efficient Dispute Resolution: Visa Dispute Resolution Network streamlines pre-dispute handling so merchants can resolve potential disputes before they escalate, accelerating resolution, reducing operational burden. Pilot available now with general availability planned for late 2026.
• AI-Driven Revenue Recovery: Visa Dispute Recovery Manager automates representment for merchants – managing disputes with GenAI responses and providing win prediction scoring to maximize recovery. Pilot expansion planned for late 2026.
• Proactive Dispute Prevention: Order Insight helps prevent unnecessary disputes by surfacing transaction details to clear up confusion over legitimate charges. An April 2026 update means merchants can use Compelling Evidence 3.0 within Order Insight to share evidence with banks regarding suspicious transactions, further reducing friendly fraud instances.

 

New & Enhanced Dispute Resolution Tools for Issuers & Acquirers

 

• Empowering Agents: Dispute Intelligence is powered by predictive AI models, aiding case‑by‑case analysis with network‑wide foresight to empower agents to make more informed decisions using Visa’s global transaction and dispute data. Generally available now.
• Streamlined Review: Dispute Doc Analyzer uses AI to enable faster, more confident dispute resolution outcomes. For issuers, this tool will provide summaries of merchant documents including key data elements in a structured format to help analysts with time consuming manual review and dispute decisions (available in late April 2026). For acquirers, Doc Analyzer facilitates the ability to auto-populate response questionnaires on behalf of their merchants (generally available now).
• AI-Powered Dispute Platform: Visa Dispute Case Manager incorporates AI functionality to unify workflows into a centralized platform for managing disputes across a variety of card networks, from intake to resolution. General availability in North America in 2026.

 

“Disputes put strain on every part of the payments ecosystem, frustrating consumers, while driving cost and complexity for merchants and financial institutions,” said Andrew Torre, President of Value-Added Services, Visa. “When outdated technology cannot keep pace, fraud goes undetected. Our expanded suite of dispute services gives clients the visibility they need to focus on what matters most: serving customers, launching new products and growing their businesses.”

 

For more information on these products, please visit Visa’s Value-Added Services website here: https://corporate.visa.com/en/solutions/value-added-services.html

 

 

About Visa

 

 

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

 

 

¹ VisaNet transaction data 2019-2025

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401900827/en/

 

Business Wire India

VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company’s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.

 

The IDE approval enables initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation (TR).

 

 

“This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” said Mike Buck, Chief Executive Officer. “Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.”

 

 

Significant unmet clinical needs exist in the treatment of TR with 1.5 million people in the US suffering from TR with a small percentage of those patients eligible to receive surgical treatment.² Severe TR is linked to poor prognosis and high mortality (10% at one year), yet current treatment options remain extremely limited³.

 

 

VDYNE’s TTVR system is designed as a patient-tailored, minimally invasive solution to address the complexities of tricuspid valve anatomy and disease. Since first-in-human use in November 2023, the system has been used globally through clinical studies and compassionate use, providing important insights into procedural performance and clinical outcomes.

 

 

About VDYNE, Inc.

 

 

VDYNE, Inc. is a privately held medical device company focused on developing innovative transcatheter valve replacement technologies for the treatment of tricuspid regurgitation. Headquartered in Maple Grove, Minnesota, VDYNE is dedicated to transforming care for patients suffering from right heart valve disease.

 

 

The VDYNE Tricuspid Valve Replacement System is currently under clinical investigation and not commercially available in the United States or any other country.

 

 

About Tricuspid Regurgitation

 

 

Tricuspid regurgitation (TR) occurs when the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium. This condition can lead to fatigue, fluid retention, and reduced quality of life and is associated with significant mortality and morbidity.

 

 

[1] TRIVITA Trial: VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients with Symptomatic Severe Tricuspid Valve Regurgitation
[2] Demir OM, Regazzoli D, Mangieri A, Ancona MB, Mitomo S, Weisz G, Colombo A, Latib A. Transcatheter Tricuspid Valve Replacement: Principles and Design. Front Cardiovasc Med. 2018 Sep 19;5:129. doi: 10.3389/fcvm.2018.00129. PMID: 30283790; PMCID: PMC6156134.
[3] Kolte D, Elmariah S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020 Feb;10(1):89-97. doi: 10.21037/cdt.2019.09.11. PMID: 32175231; PMCID: PMC7044094.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401672745/en/

 

Business Wire India

Dettol, India’s leading germ protection brand, launches a heartfelt new campaign for its iconic Dettol Antiseptic Liquid, with an emotion-led narrative that strengthens the brand’s connection with families while highlighting its unmatched protection. Built on the universal truth of a mother’s instinctive care, the campaign brings to life the thought: “Nothing protects like Mom & Dettol.”

 

For generations, Dettol has been more than just a product, it has been a reassuring presence in moments of vulnerability. The new film captures this emotional essence through a tender moment set in the lively chaos of a shaadi ka ghar. Amid the celebrations, a young boy hurts himself and hides his injury from others, putting on a brave face. But the moment he reaches his mother, she instinctively senses something is wrong. As she tends to his wound with Dettol Antiseptic Liquid, his guard drops, revealing his pain, only to be followed by a touching role reversal, where he comforts her instead.

 

The film concludes with the message: “Apnon ki suraksha ka mazboot sahara.” It reaffirms Dettol’s timeless place in Indian homes, standing beside mothers in moments where love is instinctive, and protection is assured.

 

The film is brought to life with the concept and film written by Prasoon Joshi, original track by Vishal Khurana, sung by Javed Ali, lyrics by Prasoon Joshi, direction by Amit Sharma, weaving together emotion, culture, and authenticity.

 

Commenting on the launch, Gaurav Jain, EVP Regional Director, Reckitt – South Asia, said, “At Reckitt, we believe our responsibility goes far beyond delivering products—we are here to build a world where people feel safe, protected and empowered to care for one another. Dettol stands at the heart of this mission. Its legacy spans generations, becoming a silent but steadfast companion in homes across India. It is a brand that shows up not only in moments of need, but in moments of emotion, times when a mother’s instinct takes over, when a child’s tears are hidden behind bravery, when protection is both physical and deeply personal. This campaign encapsulates that delicate, human truth: a mother senses hurt even before it is spoken, and Dettol strengthens her ability to respond with care and confidence. Together, a mother’s instinct and Dettol’s protection create a bond that generations have trusted and will continue to trust for years to come.”

 

Prasoon Joshi, Chairman, Omnicom India, said, “I really enjoyed writing this simple, storytelling-led piece of brand communication. Dettol has always stood for care and protection. Because when a child is hurt, no matter how big or small, the first instinct is to reach for their mother, their ultimate safe space. And in that moment, the mother turns to Dettol, something she trusts to protect what matters most. This is the bond we wanted to bring alive. A bond of quiet care, instinctive love, and unwavering trust, something we never really outgrow. This would not have been possible without a committed team, at Reckitt, and at Chrome, Amit Sharma’s sensitive direction, along with the performances and the music brought alive by Vishal Khurana and Javed Ali.”

 

As the heart of the Dettol portfolio, Dettol Antiseptic Liquid continues to offer unmatched protection for cuts and wounds, reinforcing its role in safeguarding families across generations. Whether it’s a scraped knee, a sudden fall, or a quiet, hidden tear, Dettol has stood by mothers as the strong partner that helps them protect the ones they love most.

 

Through this campaign, Dettol reaffirms its enduring place in Indian households, standing shoulder to shoulder with mothers in life’s most vulnerable moments, where care is instinctive and protection is unmatched.

 

Link to TVC: https://youtu.be/UqeskegtsIw

 

Written & Conceptualised by Prasoon Joshi (Chairman- Omnicom India)

Agency: McCann, Gurgaon

Creative Team: Prasoon Joshi, Anand Bhushan, Ashish Nath, Rajesh Chandra

Account management: Srijib Malik, Tanisha Sharma, Saumya Sharma

Films Team: Jeet Kalra

Planning: Sumeer Mathur, Madhavi Karunakaram Guha, Aditi Jain

Director: Amit Sharma

Production house: Chrome Pictures

Business Wire India

 

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460).

 

Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership.

 

 

Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and in vivo efficacy systems, as well as its AI-driven antibody discovery platform built on real human antibody sequences, to support the development of novel antibody therapeutics. By combining the complementary strengths of both parties, the partnership aims to accelerate the advancement of promising molecules toward clinical and commercial success.

 

 

Dr. Yuelei Shen, President and CEO of Biocytogen, stated: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical. Leveraging our proprietary platforms, Biocytogen has built a comprehensive pipeline of next-generation therapeutic modalities, including bispecific and multispecific antibodies, ADCs, VHHs, and TCR-based therapeutics. This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”

 

 

About Biocytogen

 

 

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

 

 

Biocytogen has independently developed its proprietary RenMice^® (RenMab^®/RenLite^®/RenNano^®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

 

 

About Sihuan Pharmaceutical

 

 

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401580773/en/

 

Business Wire India

The Net Green Foundation High Impact Sustainability Dialogue & Earth Awards 2026, organised at UNESCO House, New Delhi, successfully brought together policymakers, sustainability leaders, industry experts, academicians, civil society representatives, and young innovators. The event witnessed the participation of over 125 distinguished attendees.

During the ceremony, the Net Green Foundation Earth Awards 2026 honoured more than 25 outstanding individuals, organisations, and initiatives for their remarkable contributions to environmental conservation, climate action, water sustainability, clean energy, circular economy, and community-driven sustainability.

The event was supported by key government institutions, including the Ministry of Environment, Forest and Climate Change, the Ministry of Jal Shakti, and the Department of Water Resources, River Development and Ganga Rejuvenation, Government of India, Uttar Pradesh Industrial Development Authority, along with the national movement Mission LiFE.

Shri Sardar Manjinder Singh Sirsa, Hon’ble Minister of Industries, Food & Supplies and Environment, Forest & Wildlife, Government of NCT of Delhi was Chief guest of the event, while Shri Acharya Balkrishna ji was the Guest of Honour. Natural Sciences Programme Specialist at UNESCO India, Dr Benno Böer, was the special guest at the event.

Earlier, the programme opened with the Welcome Address by Ms Surbhi Gupta, Director, Net Green Foundation. Ms Neha Edwin, Senior Vice President, Net Green Foundation, delivered the Opening Address. Mr Umesh Kumar Sharma, Director and Editor-in-Chief, and Ms Vaanii Hiremath, Director, Net Green Foundation, were also present on the occasion.

Domain experts and thought leaders have underlined urgency for action toward building sustainable and climate-resilient communities to ensure a sustainable future. The experts have also pointed out the importance of collective action in protecting ecosystems.

Discussing sustainability issues at the Net Green Foundation High-Impact Knowledge Exchange & Earth Awards 2026 at UNESCO House, here, a panel moderated by Dr Rajeev Jindal, Professor of Practice, Department of Design, IIT Kanpur, explored various issues including corporate sustainability leadership, responsible infrastructure development, water stewardship, and the role of financial institutions in enabling green initiatives.

Another panel discussed issues related to community engagement, climate leadership, environmental education, and the importance of collective action in protecting ecosystems. This was moderated by Dr Lipika Sharma, Senior Consultant (Gender & Climate Expert) – UN Women.

Eminent panelists included Mr Debasis Satapathy, Chief General Manager (HRM), NBCC Limited; Mr Kamal Chugh, Head – Government & Institutional Business (North India), Federal Bank Limited; Dr Santanu Basu, Project Director – Harit, HCL Foundation; and Ms Rajni Dhiman, Head of Department- Water, Ramboll India Pvt. Ltd. Ms Tanish Maheshwari, Head – Communications & Advocacy, DLF Foundation, Prof. Vivek Kumar, Professor, IIT Delhi, Prof. C.R. Babu, Professor Emeritus, Centre for Environmental Management of Degraded Ecosystems (CEMDE), University of Delhi and Swami Prem Parivartan (Peepal Baba), Founder, Give Me Trees Trust.

A number of institutions including the Federal Bank, Zee, South Eastern Coalfields Limited, Radha TMT, and SUEZ India Foundation, were partners in the initiative.

The event reaffirmed the Foundation’s commitment to building a powerful ecosystem that celebrates sustainability leadership, encourages innovation, and fosters partnerships for a greener and more resilient future. Through such initiatives, the Foundation continues to create platforms that inspire action, innovation, and measurable environmental impact across India.

 

Business Wire India

• A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases
• Colorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50

 

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy.

 

This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enabling study for BOT+BAL enrolling approximately 830 patients and is expected to complete global enrollment quickly, reflecting the unprecedented investigator and patient enthusiasm worldwide, including strong interest from sites and physicians engaged through Agenus’ paid named patient and French AAC access programs.

 

 

“Enrollment of the first patient in the BATTMAN study marks a key milestone for Agenus and the BOT+BAL program,” said Dr. Steven O’Day, Chief Medical Officer, Agenus. “This study advances our goal of developing effective immunotherapies for patients who currently have few options. We’re grateful to our partners at CCTG, GI Cancer Trials in Australia, and PRODIGE and to the dedicated investigators, site staff, and patients driving this global effort.”

 

 

“Our collaboration with Agenus builds on years of cooperative-group research aimed at bringing immunotherapy benefits to patients with microsatellite-stable colorectal cancer—those historically left without effective options,” said Dr.Chris O’Callaghan, DVM, PhD, Senior Investigator, Canadian Cancer Trials Group. “Earlier CCTG studies suggested that doublet immunotherapy could extend survival even in cold tumors, and the magnitude and durability of responses seen with botensilimab and balstilimab in earlier studies warrant their investigation in a phase 3 trial.”

 

 

“The enthusiasm among investigators has been remarkable—within days of Health Canada submission, leading centers across Canada moved to open the study. We’re eager to advance this global effort and potentially transform outcomes for patients who have exhausted all other treatments,” said Dr. Jonathan Loree, MD, MSc, FRCPC, CO.33 Study Chair.

 

 

About the BATTMAN (CO.33) Trial

 

 

The BATTMAN (CCTG CO.33) (NCT07152821) trial is a global Phase 3, randomized, controlled study evaluating botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer. Conducted as an international cooperative group study led by the Canadian Cancer Trials Group (CCTG), the trial will enroll approximately 830 patients across more than 100 sites in Canada, France, Australia, and New Zealand. Participating academic networks include CCTG, the GI Cancer Trials, and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE), sponsored by UNICANCER. This registrational-enabling study is designed to support potential regulatory submissions for BOT+BAL in this difficult-to-treat patient population. Patients interested in learning more about the study, including eligibility and enrollment information, can visit: https://www.ctg.queensu.ca/patients/colorectal-cancer-clinical-trial-co33.

 

 

About Agenus

 

 

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

 

 

About Canadian Cancer Trials Group (CCTG)

 

 

The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies across Canada, and internationally. Headquartered at Queen’s University, CCTG has supported more than 700 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG’s aim is to improve survival and quality of life for all people with cancer. Learn more at cctg.ca.

 

 

About Botensilimab (BOT)

 

 

Botensilimab (BOT) is a human Fc enhanced multifunctional anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

 

 

Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov.

 

 

About Balstilimab (BAL)

 

 

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

 

 

Forward-Looking Statements

 

 

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2024, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401039214/en/

 

Business Wire India

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today.

 

Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology.

 

 

Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch.

 

 

Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering.

 

 

Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programme offers an efficient and transparent way for implementers to access the relevant SEPs of the participating patent owners under fair, reasonable and non-discriminatory (FRAND) terms.

 

 

“Cellular technology has revolutionised the payments experience for both purchasers and vendors, and the new Sisvel POS pool will make accessing it more efficient and transparent,” says programme manager Sven Törringer. “As new licensors are expected to join soon, the programme is set to become even more compelling. This is an exciting day for Sisvel and the POS market. We thank Huawei, LG Electronics and Nokia for their leadership.”

 

 

About Sisvel

 

 

Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field through the development and implementation of flexible, accessible, commercialisation solutions.

 

 

Sisvel | We Power Innovation

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401838616/en/

 

Business Wire India

Summer heat, humidity, and strong sunlight can affect how your skin behaves. Sweat, dust, and UV exposure may lead to oiliness, tanning, breakouts, and dullness. Building a simple summer vanity with the right skincare essentials and healthy habits can help keep your skin fresh, protected, and glowing even during the hottest days.

1. Sunscreen is your non-negotiable step

Daily sun exposure can lead to tanning, dark spots, and premature ageing, making sunscreen the most important step in any summer routine. Choose a broad-spectrum sunscreen with SPF 30 or higher and apply it to the face, neck, and other exposed areas 15–20 minutes before stepping outdoors. Reapply every two to three hours, especially if you are sweating or spending extended time in the sun.

Products that combine sun protection with skincare benefits can also simplify your routine. For instance, NIVEA Luminous Even Day Cream SPF 50 helps protect skin with UVA/UVB filters, while Thiamidol works to target dark spots at the source. With hyaluronic acid for hydration and up to 12-hour oil control, it helps maintain a fresh, even-looking complexion during hot and humid weather. It’s a perfect mix of moisturiser & sun protection.

2. Gentle cleansing keeps skin clear

Summer weather increases sweat and oil production, which can clog pores and trigger breakouts. Washing your face twice a day with a mild cleanser helps remove sweat, sunscreen, and pollution without damaging the skin barrier. If your skin feels extra oily in humid weather, light gel-based cleansers can help keep pores clear while maintaining balance.

3. Stay hydrated throughout the day

Hydration plays a major role in maintaining healthy skin during summer. Drinking adequate water throughout the day helps maintain moisture levels and supports overall skin health. Include fruits with high water content, like watermelon, cucumber, oranges, and berries, to keep your body cool and hydrated.

4. Wear breathable fabrics

What you wear can also impact your skin in hot weather. Tight or synthetic fabrics may trap sweat and increase irritation. Opt for loose, breathable fabrics like cotton or linen, which allow air circulation and help prevent sweat rashes and body acne.

5. Avoid peak sun hours when possible

The sun is strongest between 10 AM and 4 PM. When possible, limit prolonged exposure during these hours. Using hats, umbrellas, wearing sunglasses, or seeking shade can reduce UV exposure and help prevent tanning and sunburn.

6. Exfoliate gently, but not too often

Sweat and sunscreen buildup can leave skin feeling dull. Gentle exfoliation once or twice a week can help remove dead skin cells and keep pores clear. Avoid harsh scrubs or excessive exfoliation, which may irritate skin already stressed by heat and sun.

7. Keep your routine simple and consistent

Summer skincare works best when routines are minimal and consistent. Focus on a few essential steps: cleanse, hydrate, protect, and treat specific concerns like pigmentation or acne. A thoughtfully curated summer vanity paired with healthy habits can help your skin stay comfortable, protected, and radiant all season long.

Business Wire India

Danube Properties has unveiled Greenz By Danube, its first large-scale integrated community featuring premium townhouses and villas – marking a major milestone in its expansion into master-planned developments.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401810554/en/

 

 

 

Strategically located in Dubai International Academic City, near Dubai Silicon Oasis, Greenz sits within one of Dubai’s most promising future growth corridors. The area is home to over 100,000 residents and will benefit from the upcoming District IO, a major technology hub aligned with the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum.

 

Featuring villas and townhouses with exclusive sky gardens, Greenz By Danube’s completion is expected in 36 to 40 months with handover scheduled for Q4 2029.

 

 

Rizwan Sajan, Founder and Chairman of Danube Group, said: “Greenz by Danube sets new benchmark for premium master communities – a first-of-its-kind living experience in Dubai. Designed with low-density planning, it ensures prime location and high appreciation guarantee. With 50+ luxury amenities and fully furnished, designer-curated interiors with Dolce Vita, every detail reflects elegance and distinction. Greenz is not just a community – it is a luxury lifestyle experience of a lifetime.”

 

 

The development offers 3- and 4-bedroom townhouses, 5-bedroom semi-detached villas, and 5-bedroom twin villas, catering to both families and investors.

 

 

Connectivity is a key highlight, with Emirates Road just 2 minutes away, Sheikh Mohammed Bin Zayed Road within 6 minutes, Downtown Dubai and Burj Khalifa 20 minutes away, and Dubai International Airport reachable in 17 minutes. The upcoming Blue Line Metro is expected to further enhance accessibility and long-term value.

 

 

Focused on lifestyle and wellness, Greenz will feature 50+ amenities across five hubs, including beach-inspired spaces, sports courts, fitness and recovery zones, green areas, and family spaces.

 

 

With prices starting from AED 3.5 million and a flexible 1% monthly payment plan, Greenz presents a strong investment opportunity in a high-growth location.

 

 

About Danube Properties

 

 

Danube Properties, a subsidiary of the Danube Group founded in 1993 by Rizwan Sajan, is among the UAE’s leading private real estate developers. Known for pioneering the 1% payment plan, the company delivers fully furnished apartments complemented by over 40 lifestyle amenities, with a strong track record of quality construction and timely delivery.

 

 

Source: AETOSWire

 

 

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260401810554/en/